Vericel Corp Files 2024 10-K

Ticker: VCEL · Form: 10-K · Filed: Feb 27, 2025 · CIK: 887359

Sentiment: neutral

Topics: 10-K, annual-report, financials

TL;DR

VCEL filed its 2024 10-K. Full financials and biz details out now.

AI Summary

Vericel Corp filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, previously known as Aastrom Biosciences Inc., is engaged in the biological products sector. Key financial figures and operational details for 2024 are presented in this comprehensive annual filing.

Why It Matters

This filing provides investors and stakeholders with a detailed overview of Vericel Corp's financial health, operational performance, and strategic direction for the past fiscal year.

Risk Assessment

Risk Level: medium — The filing is a standard annual report and does not inherently indicate new risks.

Key Numbers

Key Players & Entities

FAQ

What were Vericel Corp's total revenues for the fiscal year ended December 31, 2024?

Vericel Corp reported total revenues of $389 for the fiscal year ended December 31, 2024.

What was Vericel Corp's net income for the fiscal year ended December 31, 2024?

Vericel Corp reported a net income of $303 for the fiscal year ended December 31, 2024.

What was Vericel Corp's operating income for the fiscal year ended December 31, 2024?

Vericel Corp reported an operating income of $361 for the fiscal year ended December 31, 2024.

When was Vericel Corp previously known as?

Vericel Corp was formerly known as Aastrom Biosciences Inc., with a name change date of April 28, 1996.

What is Vericel Corp's primary business classification?

Vericel Corp is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code [2836].

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Vericel Corp (VCEL).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing